SCHEMBL22280710

SCHEMBL22280710

CC(C)c1cccc(C(C)C)c1-c1ccc2c3ccc(Oc4ccc5c6ccccc6n(-c6ccccn6)c5c4)cc3c3nc4ccccc4n3c2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.34
KDM4E B2RXH2 6/20 0.33
HSD17B10 Q99714 4/20 0.33
NPC1 O15118 4/20 0.33
HPGD P15428 3/20 0.33
TP53 P04637 3/20 0.33
RAB9A P51151 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
TSHR P16473 2/20 0.33
MAPK1 P28482 2/20 0.33
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
USP2 O75604 1/20 0.33
LMNA P02545 2/20 0.33
PKM P14618 1/20 0.33
PPARG P37231 1/20 0.32
FLT3 P36888 1/20 0.32
KMT2A Q03164 4/20 0.32
MAPT P10636 2/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22280943 0.89 CYP3A4 (0.31) CYP3A4
SCHEMBL22280701 0.87 ALDH1A1 (0.39) ALDH1A1KDM4EHSD17B10NPC1HPGD
SCHEMBL22281117 0.86 PPARG (0.31) PPARGPDE10A
SCHEMBL21917498 0.85 HSD17B10 (0.39) ALDH1A1KDM4EHSD17B10NPC1HPGD
SCHEMBL20561393 0.83 HSD17B10 (0.37) ALDH1A1KDM4EHSD17B10NPC1HPGD
SCHEMBL12076945 0.81 PPARG (0.32) PPARG
SCHEMBL29808063 0.81 PPARG (0.32) PPARG
SCHEMBL21917500 0.81 PDE10A (0.37) ALDH1A1KDM4EHSD17B10NPC1HPGD
SCHEMBL21917499 0.80 HSD17B10 (0.36) ALDH1A1KDM4EHSD17B10NPC1HPGD
SCHEMBL21917583 0.80 HSD17B10 (0.37) ALDH1A1KDM4EHSD17B10NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200239505-A1 BLUE PHOSPHORESCENT EMITTERS EMPLOYING FUNCTIONALIZED IMIDAZOPHENTHRIDINE AND ANALOGUES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2020-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239505-A1 BLUE PHOSPHORESCENT EMITTERS EMPLOYING FUNCTIONALIZED IMIDAZOPHENTHRIDINE AND ANALOGUES EML4, TYR, TYMP ALDH1A1 2652/4885KDM4E 1356/4885HSD17B10 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.